Phase 2 Study of Treatment for ALS-Induced Cramps, FLX-787, Underway in Australia
Flex Pharma has begun a Phase 2 clinical trial assessing FLX-787 in patients with amyotrophic lateral sclerosis (ALS). The aim of the study, taking place in Australia, is to evaluate the safety and efficacy of FLX-787 in treating ALS-related leg cramps and/or spasticity. Patients with ALS — a…